BLCM Bellicum Pharmaceuticals Inc

Bellicum Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The firm is primarily engaged in the research of cellular immunotherapies for hematological cancers, solid tumors, and orphan inherited blood diseases.

$1.44
As of 05/25/2022     IEX book   CBOE book

---

Security Information

---

Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  12/18/2014
Outstanding shares:  8,609,661
Average volume:  23,525
Market cap:   $11,623,042
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      

---

Valuation   (See tab for details)

---

PE ratio:   11.42
PB ratio:   0.72
PS ratio:   0.00
Return on equity:   21.20%
Net income %:   0.00%